Immunome Stock Today
| IMNM Stock | USD 11.53 0.38 3.41% |
Performance0 of 100
| Odds Of DistressLess than 49
|
Immunome is selling at 11.53 as of the 27th of November 2024; that is 3.41 percent increase since the beginning of the trading day. The stock's lowest day price was 10.82. Immunome has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Immunome are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of October 2020 | Category Healthcare | Classification Health Care |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.42 M outstanding shares of which 10.47 M shares are currently shorted by private and institutional investors with about 18.28 trading days to cover. More on Immunome
Moving together with Immunome Stock
| 0.84 | ME | 23Andme Holding | PairCorr |
| 0.8 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Immunome Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immunome Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Clay Siegall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmunome can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunome's financial leverage. It provides some insight into what part of Immunome's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunome (IMNM) is traded on NASDAQ Exchange in USA. It is located in 18702 N. Creek Parkway, Bothell, WA, United States, 98011 and employs 55 people. Immunome is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 695.95 M. Immunome conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.42 M outstanding shares of which 10.47 M shares are currently shorted by private and institutional investors with about 18.28 trading days to cover.
Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86.
Check Immunome Probability Of Bankruptcy
Ownership AllocationImmunome has a total of 62.42 Million outstanding shares. The majority of Immunome outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunome to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunome. Please pay attention to any change in the institutional holdings of Immunome as this could imply that something significant has changed or is about to change at the company. Also note that almost one hundred fourty-nine thousand eight hundred invesors are currently shorting Immunome expressing very little confidence in its future performance.
Check Immunome Ownership Details
Immunome Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Opaleye Management Inc | 2024-09-30 | 1.2 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.2 M | |
| Vestal Point Capital Lp | 2024-06-30 | 1000 K | |
| Woodline Partners Lp | 2024-06-30 | 922.9 K | |
| Avidity Partners Management Lp | 2024-09-30 | 873.9 K | |
| Brown Advisory Holdings Inc | 2024-09-30 | 860.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 743.9 K | |
| Victory Capital Management Inc. | 2024-09-30 | 730.8 K | |
| Tang Capital Management Llc | 2024-09-30 | 720 K | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 5.8 M | |
| Redmile Group, Llc | 2024-09-30 | 4.9 M |
Immunome Historical Income Statement
Immunome Stock Against Markets
Immunome Corporate Management
| Matthew Robinson | Chief Officer | Profile | |
| Michael Morin | Chief Scientist | Profile | |
| Philip Roberts | Chief Officer | Profile | |
| Robert Lapetina | Principal Officer | Profile | |
| JD Esq | General Officer | Profile | |
| Purnanand Sarma | CEO Pres | Profile | |
| Sandra Esq | Gen Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.